Tislelizumab for the treatment of advanced esophageal squamous cell carcinoma.

IF 3 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2025-05-01 Epub Date: 2025-04-21 DOI:10.1080/14796694.2025.2495542

Kazuhiro Shiraishi, Shun Yamamoto, Ken Kato

{"title":"Tislelizumab for the treatment of advanced esophageal squamous cell carcinoma.","authors":"Kazuhiro Shiraishi, Shun Yamamoto, Ken Kato","doi":"10.1080/14796694.2025.2495542","DOIUrl":null,"url":null,"abstract":"<p><p>Advanced esophageal squamous cell carcinoma (ESCC) patients had poor prognosis and few effective drugs based on the randomized controlled trials (RCTs). In such a circumstance, recent RCTs have shown the clinical efficacy of immune checkpoint inhibitors (ICIs) as first- or second-line treatment for advanced ESCC patients. Tislelizumab is one of the anti-Programmed-Death-1 (PD-1) antibodies; at first, tislelizumab monotherapy showed clinical efficacy as a second-line treatment for advanced ESCC patients based on the results of the RATIONALE-302 trial. Since then, tislelizumab plus doublet chemotherapy has shown superiority in overall survival compared to doublet chemotherapy for untreated advanced ESCC patients in the RATIONALE-306 trial. In this review, we share the overview of the development of tislelizumab and discuss the future perspectives on ICIs for advanced ESCC patients. In our opinion, tislelizumab plus doublet chemotherapy is one of the first-line standard treatments for advanced ESCC patients regardless of Programmed cell Death ligand 1 expression. Some other ICI-containing treatments showed clinical efficacy for untreated ESCC patients; we need further investigation to select these treatments appropriately.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":"21 12","pages":"1473-1481"},"PeriodicalIF":3.0000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12077467/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2025.2495542","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/21 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Advanced esophageal squamous cell carcinoma (ESCC) patients had poor prognosis and few effective drugs based on the randomized controlled trials (RCTs). In such a circumstance, recent RCTs have shown the clinical efficacy of immune checkpoint inhibitors (ICIs) as first- or second-line treatment for advanced ESCC patients. Tislelizumab is one of the anti-Programmed-Death-1 (PD-1) antibodies; at first, tislelizumab monotherapy showed clinical efficacy as a second-line treatment for advanced ESCC patients based on the results of the RATIONALE-302 trial. Since then, tislelizumab plus doublet chemotherapy has shown superiority in overall survival compared to doublet chemotherapy for untreated advanced ESCC patients in the RATIONALE-306 trial. In this review, we share the overview of the development of tislelizumab and discuss the future perspectives on ICIs for advanced ESCC patients. In our opinion, tislelizumab plus doublet chemotherapy is one of the first-line standard treatments for advanced ESCC patients regardless of Programmed cell Death ligand 1 expression. Some other ICI-containing treatments showed clinical efficacy for untreated ESCC patients; we need further investigation to select these treatments appropriately.

查看原文本刊更多论文

Tislelizumab用于治疗晚期食管鳞状细胞癌。

根据随机对照试验（RCTs），晚期食管鳞状细胞癌（ESCC）患者预后较差，且有效药物较少。在这种情况下，最近的随机对照试验显示免疫检查点抑制剂（ICIs）作为晚期ESCC患者的一线或二线治疗的临床疗效。Tislelizumab是一种抗程序性死亡-1 （PD-1）抗体；首先，基于RATIONALE-302试验的结果，tislelizumab单药治疗作为晚期ESCC患者的二线治疗显示出临床疗效。从那时起，在RATIONALE-306试验中，tislelizumab +双重化疗在未治疗的晚期ESCC患者的总生存期中显示出优于双重化疗的优势。在这篇综述中，我们分享了tislelizumab的发展概况，并讨论了晚期ESCC患者使用ICIs的未来前景。我们认为，无论程序性细胞死亡配体1的表达如何，tislelizumab加双重化疗是晚期ESCC患者的一线标准治疗之一。其他一些含ici的治疗方法对未经治疗的ESCC患者有临床疗效；我们需要进一步的研究来选择合适的治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.